Megan Curry
Medical · Blacksville, WVNPI 1508267196
Payments from drug & device makers
Across 127 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$449
- Abbott$321
- Lilly USA, LLC$252
- Boehringer Ingelheim$129
- Merck$98
- Novo Nordisk$82
- plus $831 from 24 others
What the payments were for
- Food & beverage$2,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $449 |
| Abbott | 15 | $321 |
| Lilly USA, LLC | 15 | $252 |
| Boehringer Ingelheim | 8 | $129 |
| Merck | 6 | $98 |
| Novo Nordisk | 4 | $82 |
| Pfizer | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| GSK | 4 | $67 |
| Currax Pharmaceuticals LLC | 4 | $57 |
| Organon | 3 | $51 |
| Johnson & Johnson | 3 | $44 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Novartis | 2 | $34 |
| AstraZeneca | 2 | $33 |
| Verona Pharma, Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Lundbeck LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Biogen | 1 | $19 |
| Scynexis, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Amgen | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$2,162 in reported general payments places this provider in the 70th percentile of 233 medical providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $19,067 |
| MounjaroTirzepatide | 14 | $16,296 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,112 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $2,651 |
| Ventolin HfaAlbuterol Sulfate | 30 | $1,625 |
| Colestipol Hcl | 13 | $1,609 |
| Atorvastatin Calcium | 121 | $1,163 |
| Omeprazole | 98 | $1,130 |
| Levothyroxine Sodium | 87 | $1,018 |
| Metoprolol Succinate | 43 | $823 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $722 |
| Ezetimibe | 32 | $608 |
| Diclofenac Sodium | 21 | $594 |
| Bupropion XlBupropion Hcl | 29 | $570 |
| Lisinopril | 93 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $82 | $19,06717 claims |
| Lilly USA, LLCMounjaro | $252 | $16,29614 claims |
| GSKIncruse Ellipta | $67 | $5,11212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 233 medical providers in West Virginia.
Other medical in Blacksville
- Katherine BoggsSouth Charleston$46K
- Lowell LarewMorgantown$31K
- Katie CarpenterSouth Charleston$26K
- Lauren DillonBeckley$18K
- Angela HagerFarmington$16K
- Brandon CaragCharleston$16K
- Scott EthridgeCharleston$16K
- Kellie HanselSouth Charleston$12K
- Matthew MaynardElkins$10K
- Mohammad YousafCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.